Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase III Randomized Trial of Anlotinib Plus Gemcitabine/Cisplatin Vesus Placebo Plus Gemcitabine/Cisplatin in Previous Untreated Patients With Recurrent/Metastatic Nasopharyngeal Carcinoma

Next Previous
Trial Profile

Phase III Randomized Trial of Anlotinib Plus Gemcitabine/Cisplatin Vesus Placebo Plus Gemcitabine/Cisplatin in Previous Untreated Patients With Recurrent/Metastatic Nasopharyngeal Carcinoma

Recruiting
Phase of Trial: Phase III

Latest Information Update: 11 Feb 2019

At a glance

  • Drugs Anlotinib (Primary) ; Cisplatin; Gemcitabine
  • Indications Carcinoma; Nasopharyngeal cancer
  • Focus Registrational; Therapeutic Use
  • Sponsors Chia Tai Tianqing Pharmaceutical Group

    • Most Recent Events

    • 10 Sep 2018 Status changed from not yet recruiting to recruiting.
    • 01 Aug 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Legal

Back to top